Regeneron's experimental anti-myostatin antibody trevogrumab cut lean mass loss by roughly 42% over 52 weeks in adults taking semaglutide for obesity, according to Phase 2 results.
An nference analysis of over 15 million medical records found 1,039 patients with documented BPC-157 use, with new users increasing 33-fold between 2020 and 2026 despite limited human safety data.
Eli Lilly's triple-agonist obesity drug retatrutide has completed its core Phase 3 program, with an FDA submission projected as early as 2027.
A preprint by nference researchers identifies 652 patients who used unapproved retatrutide, with 71.2% of those who had a documented source reporting they obtained it outside a clinical trial, mostly through online vendors.
An AJSM review of 565 studies on six widely sold peptides finds marketing outpaces clinical evidence, with arsenic and lead found in some tested products.
The FDA approved Eli Lilly's Mounjaro (tirzepatide) to reduce major cardiovascular events in adults with type 2 diabetes at high risk, based on SURPASS-CVOT trial results.
NBC News finds the U.S. lacks a comprehensive system for tracking peptide adverse events, leaving safety gaps beyond approved GLP-1 drugs.
FDA's adverse event database has recorded more than 1,700 reports tied to compounded semaglutide and tirzepatide, as regulators move to restrict compounding of these drugs.
A BMJ observational cohort of nearly 53,000 patients found tirzepatide users had a 2.9% major cardiovascular event rate versus 4.4% for sitagliptin, a 32% relative reduction.
A seventh Victorian patient has been hospitalized with acute liver toxicity from counterfeit retatrutide, with the TGA saying clustering suggests a possible contaminated batch issue.
